
Biopharmaceutical firm specializing in novel drug therapies for sleep apnea treatment.
RespireRx Pharmaceuticals, founded with a mission to develop innovative drug therapies, focuses on treating sleep apnea and other neurological conditions. The company aims to improve patient outcomes through cutting-edge biopharmaceutical research. Their primary product, CX1739, is an AMPAkine designed to enhance respiratory function in sleep apnea patients and improve bladder function in individuals with spinal cord injuries.
Notable figures associated with RespireRx include leading researchers and industry experts in neurology and pharmacology. The company has secured significant funding, including a Department of Defense award for clinical studies on CX1739. RespireRx's preclinical research has shown promising results, positioning it as a key player in the biopharmaceutical sector with a potential to make substantial impacts on treating sleep apnea and related conditions.

Respira Therapeutics

Respirics
Apnimed
apnimed.com

Axikin Pharmaceuticals

Respirogen
respirogen.com

Pulmatrix
pulmatrix.com

Pneuma Respiratory

Response Pharmaceuticals

Resolvyx Pharmaceuticals

Resilience Therapeutics

Kinaset Therapeutics
kinasettx.com

Aer Therapeutics

Theravance Biopharma
theravance.com

Collegium Pharmaceutical

CeNeRx Biopharma
cenerx.com
Companies similar to RespireRx Pharmaceuticals include Respira Therapeutics, Respirics, Apnimed and Axikin Pharmaceuticals.
RespireRx Pharmaceuticals was founded in 1987.
RespireRx Pharmaceuticals' headquarters is located in Glen Rock, NJ, US.
RespireRx Pharmaceuticals' most recent funding round was for $238.5k (USD) in November 2014.
As of Nov 17, 2014, RespireRx Pharmaceuticals has raised a total of $12.2M (USD).
RespireRx Pharmaceuticals has 2 employees as of Feb 6, 2024.